Today: 8 February 2026
Subscribe
Browse Category

Pfizer News News 25 November 2025 - 6 February 2026

Pfizer stock today: PFE edges down as Wall Street looks to Feb. 3 results update

Pfizer stock today: PFE edges down as Wall Street looks to Feb. 3 results update

NEW YORK, December 29, 2025, 2:08 PM ET — Regular session Pfizer shares dipped slightly on Monday, trading down about 0.1% at $25.06 as of 2:08 p.m. ET. The stock has moved between $24.99 and $25.19 in the regular session. The muted move matters because liquidity is thinning into year-end, leaving defensive names like large drugmakers more sensitive to sector headlines and positioning. Reuters reported trading volumes were expected to be light this week, with U.S. markets shut on Thursday for New Year’s Day. Reuters For Pfizer, the backdrop is still its long-dated reset story: investors are weighing whether its
29 December 2025
···
Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer shares closed Friday at $25.09, trading in a narrow range on light volume ahead of the New Year’s holiday. No new company press releases have appeared since Dec. 18. The stock remains below its 52-week high of $27.69, with dividend yield drawing investor focus as Wall Street weighs declining COVID revenues against future growth in oncology and obesity drugs.
27 December 2025
···
Pfizer (PFE) Stock News, Forecasts and Analyst Outlook as of Dec. 25, 2025

Pfizer (PFE) Stock News, Forecasts and Analyst Outlook as of Dec. 25, 2025

Pfizer shares closed at $25.03 on Dec. 24, ahead of Christmas, after the company issued 2026 guidance below Wall Street forecasts. The drugmaker projected 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, citing lower COVID product sales and loss of exclusivity. Pfizer declared a $0.43 per share Q1 2026 dividend, its 349th consecutive payout.
25 December 2025
···
Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer shares traded near $25.04 midday Friday after a volatile week, holding steady despite new policy headlines and a guidance reset. The company issued 2026 revenue guidance of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, both below Wall Street estimates. Pfizer also reported positive Phase 3 results for PADCEV + Keytruda in bladder cancer.
19 December 2025
···
Pfizer Stock (PFE) on Dec. 18, 2025: Latest News, 2026 Forecast, Analyst Price Targets, Dividend, and Key Catalysts

Pfizer Stock (PFE) on Dec. 18, 2025: Latest News, 2026 Forecast, Analyst Price Targets, Dividend, and Key Catalysts

Pfizer shares traded at $25.04 on Dec. 18, 2025, down 1.8% after management issued cautious 2026 guidance with revenue forecast at $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00. The company cited lower COVID product sales and patent expirations as major headwinds. Pfizer stock has dropped over 50% since early 2023. Investors remain focused on its dividend yield and oncology developments.
18 December 2025
··
Pfizer Stock (PFE) After Hours Today (Dec. 17, 2025): What to Know Before the Market Opens Thursday

Pfizer Stock (PFE) After Hours Today (Dec. 17, 2025): What to Know Before the Market Opens Thursday

Pfizer shares closed down 1.9% at $25.04 Wednesday, hitting session lows despite positive Phase 3 results for PADCEV plus KEYTRUDA in bladder cancer. The stock edged up to $25.07 after hours. Investors weighed new 2026 guidance projecting $59.5–$62.5 billion in revenue and a $1.5 billion decline in COVID-19 product sales. Broader U.S. market weakness also pressured the stock.
18 December 2025
··
Pfizer Stock (PFE) Today: 2026 Guidance Triggers Fresh Scrutiny—News, Forecasts, Analyst Targets and Dividend Outlook (Dec. 17, 2025)

Pfizer Stock (PFE) Today: 2026 Guidance Triggers Fresh Scrutiny—News, Forecasts, Analyst Targets and Dividend Outlook (Dec. 17, 2025)

Pfizer shares traded near $25.50 Wednesday after the company issued 2026 revenue guidance of $59.5–$62.5 billion and forecast adjusted EPS of $2.80–$3.00, below Wall Street expectations. The company also cut its 2025 revenue outlook to about $62 billion. Shares fell about 5% after the update. Pfizer cited lower COVID product sales and ongoing patent losses as key headwinds.
17 December 2025
···
Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Earnings Forecasts, Analyst Price Targets and Key Catalysts

Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Earnings Forecasts, Analyst Price Targets and Key Catalysts

December 17, 2025 Pfizer Inc. (NYSE: PFE) stock is back in the spotlight on December 17 as investors digest the company’s newly issued full-year 2026 financial guidance, along with a stack of fresh reporting and analyst commentary about what comes next for one of the world’s biggest drugmakers. The immediate market reaction has been skeptical: Pfizer’s outlook points to another year of flat-to-down top-line performance as COVID-era revenue continues to normalize and a looming loss-of-exclusivity (LOE) cycle begins to bite harder. Pfizer+1 As of 00:43 UTC on Dec. 17 (late Dec. 16 in New York), Pfizer shares were about $25.53,
17 December 2025
····
Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks

Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks

Pfizer (NYSE: PFE) heads into Monday’s U.S. market open (Dec. 15, 2025) in a familiar spot for late 2025: investors are weighing a high dividend and aggressive deal-making against policy uncertainty for COVID vaccines and the company’s ongoing push to replace pandemic-era revenue with oncology and cardiometabolic growth. As of Friday’s close (Dec. 12), Pfizer shares finished around $25.85, near the middle-to-upper end of a $20.92–$27.69 52-week range. MarketWatch+1 The most immediate catalyst isn’t an earnings report—it’s Pfizer’s analyst call on Tuesday, Dec. 16 at 8:00 a.m. ET, where management is scheduled to provide full-year 2026 financial guidance. That call
14 December 2025
··
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open

(SEO): Pfizer stock (NYSE: PFE) held firm after the bell on Dec. 12, 2025. Here’s the full roundup of today’s headlines, analyst targets, and what to watch before the next market session. Pfizer, Inc. (NYSE: PFE) wrapped up Friday’s session (December 12, 2025) with a modest gain, then traded narrowly higher in extended hours as investors weighed a dense mix of shareholder-return news (dividend), regulatory headlines tied to COVID vaccines, and fresh oncology trial results—plus at least one notable analyst price-target cut. One important calendar note upfront: December 13, 2025 is a Saturday, and U.S. stock markets are closed. So
13 December 2025
··
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

Pfizer Inc. (NYSE: PFE) ended the Friday, December 12, 2025 session slightly higher—and moved only modestly in after-hours trading—after a busy day of headline-driven catalysts. Investors weighed a newly declared $0.43 quarterly dividend, fresh FDA-related reporting tied to COVID-19 vaccine labeling, and late-stage oncology data involving Pfizer’s breast-cancer drug Tukysa (tucatinib). Reuters+3StockAnalysis+3Pfizer+3 Below is a detailed, publication-ready breakdown of what happened after the bell on 12/12/2025 and what to know heading into the next U.S. market session (note: U.S. stock markets do not hold a regular session on Saturday, December 13, 2025). Pfizer stock after the bell: the numbers investors
13 December 2025
··
Pfizer Stock (PFE) on December 8, 2025: Price, Dividend, New Drug Data and 2025–2030 Forecast

Pfizer Stock (PFE) on December 8, 2025: Price, Dividend, New Drug Data and 2025–2030 Forecast

Pfizer Inc. (NYSE: PFE) heads into mid‑December 2025 as one of the market’s most hotly debated “high-yield value” healthcare stocks. The share price has stabilized around the mid‑$20s after a bruising multi‑year slide, even as the company delivers solid earnings, unveils promising new clinical data, and doubles down on obesity drugs and AI-driven cost cutting. At the same time, investors are weighing a looming patent cliff, a tougher regulatory climate for vaccines, and legal setbacks tied to Pfizer’s Seagen acquisition. Below is a structured look at where Pfizer stock stands today and how major analysts and models see it over
8 December 2025
·
Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks

Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks

Pfizer, Inc. (NYSE: PFE) is back in focus on December 5, 2025, as investors weigh a near‑7% dividend yield, fresh analyst commentary, a major obesity‑drug acquisition and a slate of upcoming guidance that will shape expectations for 2026. Below is a detailed, news‑driven look at Pfizer stock today, including the latest price action, current Wall Street forecasts, and the biggest opportunities and risks now dominating the conversation. Pfizer stock price today: where things stand As of late trading on December 5, 2025, Pfizer shares are: Volatility is relatively low: one recent analysis pegs Pfizer’s rolling one‑year beta at just 0.59,
5 December 2025
···
Pfizer (PFE) Stock on December 2, 2025: Price, Metsera Deal, New FDA Risks and 2026 Outlook

Pfizer (PFE) Stock on December 2, 2025: Price, Metsera Deal, New FDA Risks and 2026 Outlook

As of late trading on Tuesday, December 2, 2025, Pfizer (NYSE: PFE) shares change hands around $25.10, down roughly 0.7% on the day and sitting in the middle of their 52‑week range of $20.92–$27.69.Yahoo Finance+1 The stock carries a dividend yield close to 7%, reflecting a generous payout but also lingering skepticism about the pharma giant’s growth post‑COVID.Pfizer+1 Today’s price is being shaped by a dense mix of headlines: a fresh FDA push to tighten vaccine oversight, a legal setback for Pfizer’s Seagen unit, the completion of a $10 billion obesity-drug acquisition, and earlier this quarter, upgraded 2025 profit guidance and new oncology approvals.Pfizer+4Investopedia+4Reuters+4 Below is
2 December 2025
·
PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

Pfizer Inc. (NYSE: PFE) is back on many traders’ screens today. As of early afternoon on Tuesday, November 25, 2025, Pfizer shares are trading around $25.65, up roughly 1.7% on the session, after touching an intraday high near $25.96 and a low around $25.24. That puts PFE stock in the middle of its 52‑week range between $20.92 and $27.69, with a market capitalization of roughly $143 billion.Stock Invest+1 Behind the modest move higher lies a busy news backdrop: Below is a detailed look at Pfizer stock today, the latest catalysts, and what they could mean for PFE’s outlook. Pfizer (PFE)
25 November 2025
···
1 2

Stock Market Today

MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

8 February 2026
MACOM shares rose 3.5% to $235.87 Friday after the company reported fiscal Q1 revenue of $271.6 million and raised its full-year data center growth outlook to 35–40%. Fidelity’s FMR LLC disclosed a 10.7% stake, while shareholder Susan Ocampo filed to potentially sell up to 100,000 shares. Stifel raised its price target to $255. MACOM expects to repay $161 million in convertible notes in March.
Go toTop